Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...

Wall Street hits record highs as payrolls surge. Explore healthcare stock movers, obesity drug breakthroughs, AbbVie deals, Centene struggles & ...

The growing incidence of infectious diseases, cancer, and chronic illnesses has substantially increased the demand for ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.

The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of ...

By contrast, mRNA vaccines developed by Moderna and BioNTech had to be developed from scratch, and quickly. Moderna stated that it took the company 63 days to move from sequencing to human trials.

Moderna is already riding high on the strength of its mRNA-based COVID-19 vaccine, but the broader potential of its technology has been shown in a new AstraZeneca-partnered candidate for heart ...

Monkeypox Vaccine and Treatment revenue is expected to grow at a CAGR of 10.20% from 2025 to 2032, reaching nearly USD 225.12 Mn by 2032.

Experts and agencies reject any link between COVID-19 vaccines and sudden cardiac deaths, citing studies showing no causal ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

Key TakeawaysThe global vaccines market reached USD 87.57 billion in 2024 and is projected to grow to USD 206.78 billion by ...